ArticleFrontiers in cell and developmental biology2025
A multi-omics features-based approach integrating immunogenicity and inflammation enhances immunotherapy benefit in clear cell renal cell carcinoma.
Article in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Programmed cell death 1 (PD-1) or PD-ligand 1 (PD-L1) blocker-based strategies have improved the survival outcomes of clear cell renal cell carcinomas (ccRCCs) in recent years, but only a small number of patients have benefited from them. Methods: In this study, we developed a multi-omics machine learning model based on inflammatory and immune signatures (TIs) to predict the response and survival of ccRCC patients to immune checkpoint blockade (ICB) therapy. The research collected RNA-seq and single-cell RNA-seq (scRNA-seq) data from more than 1,900 patients with autoimmune nephropathy and analyzed the genomic and transcriptome profiles of ccRCC patients. The predictive power of the method was validated in more than 1,000 ccRCC patients treated with ICB, and compared to single biomarkers (e.g., PD-L1 expression, TMB). Results: Inflammatory signaling was found to be strongly associated with ICB outcome, and 716 inflammation-related genes were identified that are enriched in the "lymphocyte activation regulation" pathway. The findings suggested that ccRCC patients can be categorized into two subtypes with different treatment responses and prognosis by these features. In addition, the TIs-ML model exhibited superior predictive capabilities compared to an individual biomarker (AUC > 0.997) across multiple independent datasets. It demonstrated the capacity to accurately differentiate between responders and non-responders. Furthermore, the model performed more effectively than existing genetic models and functional scores in predicting survival. Conclusion: We propose a TIs-ML prediction model based on multi-omics features that can effectively predict ICB treatment response in ccRCC patients. The model integrates inflammatory and immune features, and its high generalization ability was validated in multiple cohorts. Overall, the TIs-ML approach provides a novel method for guiding precise immunotherapy in ccRCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.